Dr. Ferris on Immunotherapy in Locally Advanced Head and Neck Cancer

Robert Ferris, MD, PhD
Published: Monday, Jun 19, 2017



Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses immunotherapy in patients with locally advanced head and neck cancer.

There has not been much improvement with treating patients who have HPV-negative head and neck cancer with radiation therapy, says Ferris.

In RTOG-3504, investigators are exploring whether adding an immunotherapy on top of concurrent chemoradiation improves survival for patients with intermediate- and high-risk disease in the locally advanced setting.
 


Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses immunotherapy in patients with locally advanced head and neck cancer.

There has not been much improvement with treating patients who have HPV-negative head and neck cancer with radiation therapy, says Ferris.

In RTOG-3504, investigators are exploring whether adding an immunotherapy on top of concurrent chemoradiation improves survival for patients with intermediate- and high-risk disease in the locally advanced setting.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x